logo
Loading...
Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
Medicine and HealthNature Communications

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

J. Zou, C. Kurhade, et al.

This study reveals the comprehensive cross-neutralization of Omicron sublineages BA.1, BA.2, and BA.3, shedding light on the varying effectiveness of neutralization in sera from BA.1-infected individuals. Conducted by experts from the University of Texas Medical Branch, this research underscores critical considerations for future COVID-19 vaccine strategies.... show more
GeneralSummaryMetrics
Abstract
The Omicron SARS-CoV-2 has several distinct sublineages, among which sublineline BA.1 was responsible for the initial Omicron surge and is now being replaced globally by BA.2, while BA.3 remains at low frequency. To understand cross-neutralization among these sublineages, the authors tested sera from BA.1-infected individuals against BA.2, BA.3, and USA/WA1-2020. BA.1-infected sera neutralized BA.1, BA.2, BA.3, and USA/WA1-2020 with geometric mean titers (GMTs) of 445, 107, 102, and 16, respectively, corresponding to 4.2-, 4.4-, and 28.4-fold lower neutralization against BA.2, BA.3, and USA/WA1-2020 relative to BA.1. These findings have implications for COVID-19 vaccine strategy.
Publisher
Nature Communications
Published On
May 26, 2022
Authors
Jing Zou, Chaitanya Kurhade, Hongjie Xia, Mingru Liu, Xuping Xie, Ping Ren, Pei-Yong Shi
DOI
https://doi.org/10.1038/s41467-022-30580-5
Tags
OmicronneutralizationBA.1BA.2COVID-19vaccine strategiesserum
Related Publications

Explore these studies to deepen your understanding

Adjacent work that informs or extends this paper's methodology and findings.

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
Medicine and Health

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

H. Ma, X. Zhang, et al.

Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron
Medicine and Health

Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron

H. Liu, C. I. Kaku, et al.

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
Medicine and Health

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

R. R. G. Machado, J. L. Walker, et al.

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
Medicine and Health

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J. Logue, R. M. Johnson, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 22+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny